Related Experiment Video
Updated: Dec 21, 2025
10:27
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.7K
Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study.
Sinan Koca1, Mehmet Beşiroğlu2, Melike Özçelik3
1Department of Medical Oncology, Goztepe Training and Research Hospital, Istanbul Medeniyet University, Istanbul, Turkey.
Summary
Pazopanib showed efficacy in treating advanced soft tissue sarcomas in Turkey, with manageable side effects. This study evaluated real-world data on pazopanib for soft tissue sarcoma patients.
Area of Science:
- Oncology
- Pharmacology
Background:
- Soft tissue sarcomas (STS) often present with poor prognosis and limited response to chemotherapy.
- Pazopanib, a multi-tyrosine kinase inhibitor, offers a potential therapeutic option for advanced STS.
Purpose of the Study:
- To assess the real-world efficacy and safety of single-agent pazopanib in Turkish patients with advanced non-adipocytic soft tissue sarcomas.
- To provide data on pazopanib's performance in a specific patient population.
Main Methods:
- A retrospective analysis of 103 patients with advanced non-adipocytic STS treated with pazopanib (800 mg daily) across eight Turkish centers.
- Evaluation of progression-free survival (PFS), overall survival (OS), and adverse events.
Main Results:
- The median PFS was 4.3 months and the median OS was 10.1 months.
- Common toxicities included fatigue, anorexia, weight loss, and nausea. Grade ≥3 toxicities involved fatigue, anorexia, weight loss, and liver disorders.
- Leimyosarcoma was the most frequent subtype (41%).
Conclusions:
- Pazopanib is an effective and tolerable treatment for patients with relapsed, advanced non-adipocytic soft tissue sarcomas.
- Patients with good performance status tolerated pazopanib well.
